I agree that Pro140 is better which is why I have CYDY. I just saw that Humanigen is making another mAb that has shown success in treating this disease in a tiny study of less than 20 people. I don't own a single share of Humanigen. After the research that I have been doing the last month I see that Cytodyn by and far has a better drug. In addition, Pro140 is applicable to treating a huge number of health issues in the future.

In terms of competitors that are not BP, I felt that Humanigen is closest to us with a mAb treatment. So I guess I have questions...

Will other investors care what the competition is doing?

Would you consider them as being competition?

Does it matter? Meaning will there a big enough demand that everybody will do well as supply lines will be very limited at the start.

These questions are not meant to be reckless. These are meant to be looking to the future and looking at competition. These are two things that a good investor must do before siding with the best choice, which I feel we all have. We should all be keeping that in mind.